Resultados de la búsqueda 491-500 of 14396 for Acute gout

  1. Ensayos clínicos - Medicina Interna Hospitalaria

    The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI) ...

  2. Ensayos clínicos - Medicina Interna Hospitalaria

    The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI) ...

  3. Salud del adulto - Mayo Clinic

    Salud del adulto. Sections. Información básica · Cómo mantener tu buena salud · Cuidado dental · Cuidado de la piel · Cuidado de las uñas ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma. Rochester, Minn ...

  5. Hematología - Ensayos clínicos

    A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma. Rochester, Minn ...

  6. Hematología - Ensayos clínicos

    A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma. Rochester, Minn ...

  7. Enfermedades infecciosas - Ensayos clínicos - Mayo Clinic

    ... severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score ≥ 32 and MELD scores 21-30, inclusive. A Study to ...

  8. Hematología - Ensayos clínicos

    A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma. Rochester, Minn ...

  9. Hematología - Ensayos clínicos

    A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma. Rochester, Minn ...

  10. Ensayos clínicos - Neurología

    ... acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) ...